Collagen-based materials,renowned for their biocompatibility and minimal immunogenicity,serve as exemplary substrates in a myriad of biomedical applications.Collagen-based micro/nanogels,in particular,are valued for t...Collagen-based materials,renowned for their biocompatibility and minimal immunogenicity,serve as exemplary substrates in a myriad of biomedical applications.Collagen-based micro/nanogels,in particular,are valued for their increased surface area,tunable degradation rates,and ability to facilitate targeted drug delivery,making them instrumental in advanced therapeutics and tissue engineering endeavors.Although extensive reviews on micro/nanogels exist,they tend to cover a wide range of biomaterials and lack a specific focus on collagen-based materials.The current review offers an in-depth look into the manufacturing technologies,drug release mechanisms,and biomedical applications of collagen-based micro/nanogels to address this gap.First,we provide an overview of the synthetic strategies that allow the precise control of the size,shape,and mechanical strength of these collagen-based micro/nanogels by controlling the degree of cross-linking of the materials.These properties are crucial for their performance in biomedical applications.We then highlight the environmental responsiveness of these collagen-based micro/nanogels,particularly their sensitivity to enzymes and pH,which enables controlled drug release under various pathological conditions.The discussion then expands to include their applications in cancer therapy,antimicrobial treatments,bone tissue repair,and imaging diagnosis,emphasizing their versatility and potential in these critical areas.The challenges and future perspectives of collagen-based micro/nanogels in the field are discussed at the end of the review,with an emphasis on the translation to clinical practice.This comprehensive review serves as a valuable resource for researchers,clinicians,and scientists alike,providing insights into the current state and future directions of collagen-based micro/nanogel research and development.展开更多
Type Ⅰ collagen hydrolysate with haematopoietic activity has shown tremendous potential for application in the functional food fields.The identification of peptide with haematopoietic activity to ensure the efficienc...Type Ⅰ collagen hydrolysate with haematopoietic activity has shown tremendous potential for application in the functional food fields.The identification of peptide with haematopoietic activity to ensure the efficiency of functional foods remains challenging because of the vast combinatorial potential of short peptides from collagen hydrolysates.In the present study,we identified a novel marker peptide(the I-1 peptide,GAAGLpGPK,p:hydroxyproline)for type I collagen with haematopoietic capabilities via theoretical sequence analysis and computational prediction of activity.The I-1 peptide was shown to increase the survival rate of haematopoietic stem cells following injury induced by 5-fluorouracil(5-FU),increasing the survival rate from 65.40 to 105.28%,thereby exhibiting significant haematopoietic activity.More importantly,the mechanism underlying the haematopoietic activity of the I-1 peptide was analogous to activate the JAK/STAT signalling pathway mediated by granulocyte‒macrophage colony‒stimulating factor.On this basis,a high-precision method for the detection of type I collagen hydrolysates was developed using the I-1 peptide(relative standard deviation=1.57%).This study not only provides novel perspectives for the exploration of haematopoietic peptides but also offers a new methodology for controlling the bioactivity of collagen-based food products.展开更多
基金This study was supported by grants from the National Natural Science Foundation of China(No.52242208)the National Natural Science Foundation of China(No.82371964)+1 种基金the Sigrid Jusélius Foundation,the Research Council of Finland(Academy Research Fellowship Grant No.354421)the European Union(ERC,BioLure,No.101115752).
文摘Collagen-based materials,renowned for their biocompatibility and minimal immunogenicity,serve as exemplary substrates in a myriad of biomedical applications.Collagen-based micro/nanogels,in particular,are valued for their increased surface area,tunable degradation rates,and ability to facilitate targeted drug delivery,making them instrumental in advanced therapeutics and tissue engineering endeavors.Although extensive reviews on micro/nanogels exist,they tend to cover a wide range of biomaterials and lack a specific focus on collagen-based materials.The current review offers an in-depth look into the manufacturing technologies,drug release mechanisms,and biomedical applications of collagen-based micro/nanogels to address this gap.First,we provide an overview of the synthetic strategies that allow the precise control of the size,shape,and mechanical strength of these collagen-based micro/nanogels by controlling the degree of cross-linking of the materials.These properties are crucial for their performance in biomedical applications.We then highlight the environmental responsiveness of these collagen-based micro/nanogels,particularly their sensitivity to enzymes and pH,which enables controlled drug release under various pathological conditions.The discussion then expands to include their applications in cancer therapy,antimicrobial treatments,bone tissue repair,and imaging diagnosis,emphasizing their versatility and potential in these critical areas.The challenges and future perspectives of collagen-based micro/nanogels in the field are discussed at the end of the review,with an emphasis on the translation to clinical practice.This comprehensive review serves as a valuable resource for researchers,clinicians,and scientists alike,providing insights into the current state and future directions of collagen-based micro/nanogel research and development.
基金supported by the Fundamental Research Funds for the Central Universities(Grant Number JD2435)the National Natural Science Foundation of China(No.52242208)Centrally Government Guided Local Science and Technology Development Fund Project(YDZX2023090).
文摘Type Ⅰ collagen hydrolysate with haematopoietic activity has shown tremendous potential for application in the functional food fields.The identification of peptide with haematopoietic activity to ensure the efficiency of functional foods remains challenging because of the vast combinatorial potential of short peptides from collagen hydrolysates.In the present study,we identified a novel marker peptide(the I-1 peptide,GAAGLpGPK,p:hydroxyproline)for type I collagen with haematopoietic capabilities via theoretical sequence analysis and computational prediction of activity.The I-1 peptide was shown to increase the survival rate of haematopoietic stem cells following injury induced by 5-fluorouracil(5-FU),increasing the survival rate from 65.40 to 105.28%,thereby exhibiting significant haematopoietic activity.More importantly,the mechanism underlying the haematopoietic activity of the I-1 peptide was analogous to activate the JAK/STAT signalling pathway mediated by granulocyte‒macrophage colony‒stimulating factor.On this basis,a high-precision method for the detection of type I collagen hydrolysates was developed using the I-1 peptide(relative standard deviation=1.57%).This study not only provides novel perspectives for the exploration of haematopoietic peptides but also offers a new methodology for controlling the bioactivity of collagen-based food products.
